Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease.

Trial Profile

Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Jun 2014

At a glance

  • Drugs Galantamine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms CIRCADIAN
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 13 Aug 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 20 Mar 2012 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 20 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top